Long‐Term Oral Administration of Probucol [4, 4‘‐(Isopropylidenedithio) bis (2, 6‐di‐t‐Butylphenol)] (DH‐581) in the Management of Hypercholesterolemia*
- 27 April 1974
- journal article
- clinical trial
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 22 (4), 167-175
- https://doi.org/10.1111/j.1532-5415.1974.tb02163.x
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Probucol in the long-term treatment of hypercholesterolaemiaCurrent Medical Research and Opinion, 1973
- Mode of action of a new hypocholesteraemic drug (DH-581) in familial hypercholesteraemiaAtherosclerosis, 1972
- Can We Prevent Heart Disease?Annals of Internal Medicine, 1971
- Serum Cholesterol, Lipoproteins, and the Risk of Coronary Heart DiseaseAnnals of Internal Medicine, 1971
- Prediction of Coronary Heart Disease Based on Clinical Suspicion, Age, Total Cholesterol, and TriglycerideCirculation, 1970
- Hypocholesterolesmic Effect of 4,4′-(Isopropylidenedithio)-Bis(2,6-di-t-Butylphenol) (Probucol)The American Journal of Clinical Nutrition, 1970
- The effect of [4,4′-(isopropylidenedithio)bis(2,6-di-t-butylphenol)] (DH-581) on serum lipids and lipoproteins in human subjectsMetabolism, 1969
- Long-Term Effects of Clofibrate (Atromid-S) on Serum Lipids in ManCirculation, 1969
- EditorialCirculation, 1965
- A REVISION OF THE SCHOENHEIMER-SPERRY METHOD FOR CHOLESTEROL DETERMINATIONJournal of Biological Chemistry, 1950